Google
Trusted Resources: News & Events
Latest announcements and gatherings
Diabetes Drug, Metformin, Suggested as ‘Breakthrough’ Treatment for Sickle Cell Anemia
Metformin, a common drug for Type 2 diabetes, could be used to “turn on” fetal hemoglobin levels in sickle cell anemia patients, according to a study by researchers at Baylor College of Medicine and Texas Children’s Cancer and Hematology Centers. The study’s lead investigator called the finding a “major breakthrough” in treating the disease.
Sickle cell patients’ adult hemoglobin causes their red blood cells to become sickle-shaped and get stuck inside the blood vessels, leading to pain and other complications. Fetal hemoglobin, a type of hemoglobin present in newborns, does not cause red blood cells to become sickle-shaped, but its production stops at about 6 months old.
+myBinderRelated Content
-
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan AfricaBackground: Hydroxyurea has proven saf...
-
Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French...Patients with sickle cell disease (SCD) ...
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
-
What Should Teens Ask Their Doctors About Hydroxyureahttps://www.youtube.com/watch?v=VZn15uXQ...
-
Ghana Launches Partnership With Novartis to Improve Diagnosis and Treatment of People With Sickle Cell DiseaseThe Government of Ghana announced a new ...
-
Hardships, and New Hope, for Sickle Cell PatientsSickle cell disease affects about 100,00...
-
CRISPR could end sickle cell disease, but signing up black patients for clinical trials will be a hard sellThe first attempts to use a groundbreaki...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.